Jeffrey A. Bailey - 08 Nov 2024 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Role
Director
Signature
/s/ Jeffrey A. Bailey
Issuer symbol
AUPH
Transactions as of
08 Nov 2024
Net transactions value
-$38,416
Form type
4
Filing time
12 Nov 2024, 19:29:43 UTC
Previous filing
21 Aug 2023
Next filing
25 Nov 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AUPH Common Stock Options Exercise +17,913 17,913 08 Nov 2024 Direct F1
transaction AUPH Common Stock Sale $38,416 -4,557 -25% $8.43 13,356 11 Nov 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AUPH Restricted Stock Units Options Exercise $0 -17,913 -100% $0.000000 0 08 Nov 2024 Common Stock 17,913 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
F2 Represents the number of shares automatically sold to cover tax withholding obligations in connection with the vesting of RSUs.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $8.37 to $8.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4 The RSUs vested one year from date of grant and have no expiration date.